development of superselective intra-arterial infusion chemotherapy for oral cancer using anti-PD-L1 antibody drug

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K19214
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 57060:Surgical dentistry-related
• Research Institution: The Nippon Dental University
• Principal Investigator: Sakuma Kaname 日本歯科大学, 新潟生命歯学部, 講師 (70733319)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: PD-1 / 局所投与 / CD8

Outline of Final Research Achievements

Background/Aim: In this study, we investigated the antitumor effect of local and systemic administration of a small amount of anti-PD-1 antibody, overall survival (OS), and the immune environment around cancer using mice. The cell line was transplanted to the back of the mouse. And the anti-PD-1 antibody was locally administered in a small dose (30 mg / body) and systemically (300 mg / body). The tumor shrinkage rate and antitumor effect were examined 29 days after the start of administration. The OS was also compared in each of the other groups. Results: The local low-dose group and the systemic group had the same antitumor effect, and both groups showed a significant difference (p <0.05) from the control group, and the OS also showed a significant prolongation. Conclusion: Local low-dose administration of anti-PD-1 antibody showed the same antitumor effect and OS as systemic normal-dose administration, suggesting that local low-dose administration in oral cancer may be useful.

Free Research Field

腫瘍学

Academic Significance and Societal Importance of the Research Achievements

近年、免疫療法は口腔がん治療の第4の柱として期待されている。 しかし、1 型糖尿病などの重篤な免疫関連有害事象 (irAE) が報告されている。 したがって、抗 PD-1 抗体を少量の動注療法で局所投与し、全身投与と同等の抗腫瘍効果が得られれば、irAE や医療費の削減につながると考えた。結果として、局所少量投与は、全身通常量投与と比較して非劣性であり、OSに関しても同等の結果であった。また、CD8やグランザイムを局所少量投与ではより強く腫瘍組織内に誘導している可能性があり、局所の少量投与は有用性が高い可能性が示唆された。これは、口腔癌における動注化学療法の有用性へ橋渡しになると考える。